Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 22

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 22
---
holders receive in the Merger? A:Immediately prior to the closing of Merger, Aptorum will complete the Domestication as a Delaware corporation. In connection with the Domestication, each then issued and outstanding Class A ordinary share of Aptorum will convert automatically, on a one -for-onebasis, into a share of common stock of Aptorum Delaware, and each then issued and outstanding Class B ordinary share of Aptorum will convert automatically into a share of common stock of Aptorum Delaware and a share of non -votingand non -convertibleSeries A preferred stock of Aptorum Delaware. Each share of Aptorum Delaware common stock that is issued and outstanding at the Effective Time will remain issued and outstanding and such shares, subject to the proposed share consolidation, iii will be unaffected by the Merger. For a more complete description of the treatment of Aptorum securities in the Merger, please see the sections titled “The Merger Agreement — Treatment of Aptorum Ordinary Shares”. Immediately after the Merger, Aptorum shareholders as of immediately prior to the Merger are expected to own approximately 30% of the outstanding shares of Aptorum following the Merger (the “Combined Company”), while DiamiR stockholders are expected to own approximately 70% of the outstanding shares of the Combined Company. Q:Why are the two companies proposing to merge? A:Aptorum and DiamiR believe that combining the two companies will create synergies, innovation and operational efficiencies that can create long term value for stockholders. Following the Merger, the Combined Company will utilize DiamiR’s biomarker panels in various clinical studies, including through collaborations with academic institutions and clinical centers in the US and other countries through its Chief Executive Officer’s extensive global medical network, expanding therapeutic focus and geographical outreach for the Combined Company. For a more complete description of the reasons for the Merger, please see the sections titled “The Merger — Aptorum’s Reasons for the Merger” and “— DiamiR’s Reasons for the Merger”. Q:What will happen to Aptorum if, for any reason, the Merger with DiamiR does not close? A:Aptorum has invested significant time and incurred, and expects to continue to incur, significant expenses related to the proposed Merger with DiamiR. In the event the Merger does not close, Aptorum will have a limited ability to continue its current operations indefinitely. Although the Aptorum board of directors may elect, among other things, to attempt to complete another strategic transaction if